GADD45α induction in the greenscreen HC indicator assay does not occur independently of cytotoxicity

Environmental and Molecular Mutagenesis

Volumn 52, Issue 1, 2011, Pages 28-34

  Olaharski, Andrew J ^a   Albertini, Silvio ^b   Mueller, Lutz ^b   Zeller, Andreas ^b   Struwe, Melanie ^b   Gocke, Elmar ^b   Kolaja, Kyle ^a  

^a Non Clinical Safety   (United States)

^b Non Clinical Safety   (Switzerland)

Author keywords

Cytotoxicity; GADD45 ; GreenScreen

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; PROTEIN GADD45ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; GENOTOXICITY; POST HOC ANALYSIS; PROTEIN INDUCTION;

BIOLOGICAL ASSAY; CELL CYCLE PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MUTAGENICITY TESTS; NUCLEAR PROTEINS;

MAMMALIA;

EID: 78651096074     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20565     Document Type: Article

References (31)

1. Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. 2002. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem 277: 40513-40519.
2. Akerman GS, Rosenzweig BA, Domon OE, McGarrity LJ, Blankenship LR, Tsai CA, Culp SJ, MacGregor JT, Sistare FD, Chen JJ, Morris SM. 2004. Gene expression profiles and genetic damage in benzo(a)pyrene diol epoxide-exposed TK6 cells. Mutat Res 549(1-2): 43-64.
3. Arriola EL, Lopez AR, Chresta CM. 1999. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene 18: 1081-1091.
4. Aubrecht J, Narla RK, Ghosh P, Stanek J, Uckun FM. 1999. Molecular genotoxicity profiles of apoptosis-inducing vanadocene complexes. Toxicol Appl Pharmacol 154: 228-235.
5. Bradley MO, Taylor VI, Armstrong MJ, Galloway SM. 1987. Relationships among cytotoxicity, lysosomal breakdown, chromosome aberrations, and DNA double-strand breaks. Mutat Res 189: 69-79.
6. Brusick D. 1986. Genotoxic effects in cultured mammalian cells produced by low pH treatment conditions and increased ion concentrations. Environ Mutagen 8: 879-886.
7. Carrier F, Zhan Q, Alamo I, Hanaoka F, Fornace AJJr. 1998. Evidence for distinct kinase-mediated pathways in gadd gene responses. Biochem Pharmacol 55: 853-861.
8. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. 2004. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci 77: 19-34.
9. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. 2005. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res 575(1-2): 61-84.
10. Galloway SM. 2000. Cytotoxicity and chromosome aberrations in vitro: experience in industry and the case for an upper limit on toxicity in the aberration assay. Environ Mol Mutagen 35: 191-201.
11. Galloway SM, Aardema MJ, Ishidate MJr, Ivett JL, Kirkland DJ, Morita T, Mosesso P, Sofuni T. 1994. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res 312: 241-261.
12. Galloway SM, Deasy DA, Bean CL, Kraynak AR, Armstrong MJ, Bradley MO. 1987. Effects of high osmotic strength on chromosome aberrations, sister-chromatid exchanges and DNA strand breaks, and the relation to toxicity. Mutat Res 189: 15-25.
13. Greenwood SK, Hill RB, Sun JT, Armstrong MJ, Johnson TE, Gara JP, Galloway SM. 2004. Population doubling: A simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results. Environ Mol Mutagen 43: 36-44.
14. Hastwell PW, Chai LL, Roberts KJ, Webster TW, Harvey JS, Rees RW, Walmsley RM. 2006. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat Res 607: 160-175.
15. Hastwell PW, Webster TW, Tate M, Billinton N, Lynch AM, Harvey JS, Rees RW, Walmsley RM. 2009. Analysis of 75 marketed pharmaceuticals using the GADD45a-GFP 'GreenScreen HC' genotoxicity assay. Mutagen 24: 455-463.
16. ICH. 1996. Guidance for Industry S2A Genotoxicity: Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals. S2A.
17. ICH. 2008. Topic S2 (R1): Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. ICH S2 (R1).
18. Ishidate MJr, Sofuni T, Yoshikawa K, Hayashi M, Nohmi T, Sawada M, Matsuoka A. 1984. Primary mutagenicity screening of food additives currently used in Japan. Food Chem Toxicol 22: 623-636.
19. Kirkland D, Aardema M, Henderson L, Muller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 584(1-2): 1-256.
20. Kirkland D, Aardema M, Muller L, Makoto H. 2006. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat Res 608: 29-42.
21. Kirsch-Volders M, Sofuni T, Aardema M, Albertini S, Eastmond D, Fenech M, Ishidate MJr, Kirchner S, Lorge E, Morita T, Walmsley RM. 2003. Report from the in vitro micronucleus assay working group. Mutat Res 540: 153-163.
22. Knight AW, Little S, Houck K, Dix D, Judson R, Richard A, McCarroll N, Akerman G, Yang C, Birrell L, et al. 2009. Evaluation of High-throughput Genotoxicity Assays Used in Profiling the US EPA ToxCast(TM) Chemicals. Regul Toxicol Pharmacol 55: 188-199.
23. Kokkinakis DM, Liu X, Neuner RD. 2005. Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): Implications to the therapy of pancreatic adenocarcinoma. Mol Cancer Ther 4: 1338-1348.
24. Olaharski A, Albertini S, Kirchner S, Platz S, Uppal H, Lin H, Kolaja K. 2009. Evaluation of the GreenScreen GADD45alpha-GFP indicator assay with non-proprietary and proprietary compounds. Mutat Res 672: 10-16.
25. Scott D, Galloway SM, Marshall RR, Ishidate MJr, Brusick D, Ashby J, Myhr BC. 1991. International commission for protection against environmental mutagens and carcinogens. Genotoxicity under extreme culture conditions. A report from ICPEMC Task Group 9. Mutat Res 257: 147-205.
26. Seeberg AH, Mosesso P, Forster R. 1988. High-dose-level effects in mutagenicity assays utilizing mammalian cells in culture. Mutagen 3: 213-218.
27. Smith ML, Kontny HU, Zhan Q, Sreenath A, O'Connor PM, Fornace AJJr. 1996. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene 13: 2255-2263.
28. Snyder RD, Green JW. 2001. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 488: 151-169.
29. Tate M, Jagger C, Billinton N, Cahill P, Walmsley RM. 2009. How does increasing cytotoxicity affect the accuracy of the Gadd45α-GFP genotoxicity screening assay: A comparison of 4 different toxicity testing methods. Available at: Accessed November 2009.
30. von der Hude W, Kalweit S, Engelhardt G, McKiernan S, Kasper P, Slacik-Erben R, Miltenburger HG, Honarvar N, Fahrig R, Gorlitz B, et al. 2000. In vitro micronucleus assay with Chinese hamster V79 cells-Results of a collaborative study with in situ exposure to 26 chemical substances. Mutat Res 468: 137-163.
31. Wu HM, Cheng JC, Wang HS, Huang HY, MacCalman CD, Leung PC. 2009. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha. Cancer Res 69: 4202-4208.